A Life-Changing Moment in a Patient with Type 1 Diabetes: Insulin Holiday

Authors

  • Muhammad Imran Butt 1. King Faisal Specialist Hospital & Research Center, Riyadh, Kingdom of Saudi Arabia 
 2. Al Faisal University, Riyadh, Kingdom of Saudi Arabia
  • Noha Mukhtar 1. King Faisal Specialist Hospital & Research Center, Riyadh, Kingdom of Saudi Arabia
  • Muhammad Riazuddin 1. King Faisal Specialist Hospital & Research Center, Riyadh, Kingdom of Saudi Arabia
  • Lama Amer 1. King Faisal Specialist Hospital & Research Center, Riyadh, Kingdom of Saudi Arabia
  • Tarek Elsayed 1. King Faisal Specialist Hospital & Research Center, Riyadh, Kingdom of Saudi Arabia

DOI:

https://doi.org/10.31661/gmj.v9i.1769

Keywords:

Autoimmunity; Insulin Secretion; Type 1 Diabetes; Autoimmune Diabetes; Islets of Langerhans; Diabetic Ketoacidosis

Abstract

Background: The diagnosis of type 1 diabetes can be a life-changing moment for our patients particularly having to live with the idea of taking insulin all their life and the barriers it can bring about. Case report: We report a patient with ten years of autoimmune type 1 diabetes treated with insulin. He was able to stop insulin in favour of oral diabetes agents after dynamic endocrine tests confirmed micro insulin secretion despite autoimmunity. Our case demonstrates that a detailed history and thorough investigations adopting a holistic approach can sometimes change the course of disease management and can leave a positive impact on the life of our patients. Conclusion: Patients with partial retention of beta-cell function in type 1 diabetes can temporarily stop insulin safely with ongoing surveillance. [GMJ.2020;9:e1769] 

References

Dabelea D, Mayer-Davis EJ, Saydah S, Imperatore G, Linder B, Divers J, et al. Prevalence of type 1 and type 2 diabetes amon https://doi.org/10.1001/jama.2014.3201PMid:24794371 PMCid:PMC4368900 Keenan HA, Sun JK, Levine J, Doria A, Aiello LP, Eisenbarth G, et al. Residual insulin production and pancreatic ß-cell turnover after 50 years of diabetes: Joslin Medalist Study. Diabetes. 2010;59(11):2846-53. https://doi.org/10.2337/db10-0676PMid:20699420 PMCid:PMC2963543 Oram RA, McDonald TJ, Shields BM, Hudson MM, Shepherd MH, Hammersley S, et al. Most people with long-duration type 1 diabetes in a large population-based study are insulin microsecretors. Diabetes Care. 2015;38(2):323-8. https://doi.org/10.2337/dc14-0871PMid:25519449 PMCid:PMC5646646 Williams GM, Long AE, Wilson IV, Aitken RJ, Wyatt RC, McDonald TJ, et al. Beta cell function and ongoing autoimmunity in long-standing, childhood onset type 1 diabetes. Diabetologia. 2016;59(12):2722-6. https://doi.org/10.1007/s00125-016-4087-0PMid:27591853 PMCid:PMC6518060 Shields BM, McDonald TJ, Oram R, Hill A, Hudson M, Leete P, et al. C-Peptide Decline in Type 1 Diabetes Has Two Phases: An Initial Exponential Fall and a Subsequent Stable Phase. Diabetes Care. 2018;41(7):1486-92. https://doi.org/10.2337/dc18-0465PMid:29880650 PMCid:PMC6027962 Kuhtreiber WM, Washer SL, Hsu E, Zhao M, Reinhold P, Burger D, et al. Low levels of C-peptide have clinical significance for established Type 1 diabetes. Diabet Med. 2015;32(10):1346-53. https://doi.org/10.1111/dme.12850PMid:26172028 PMCid:PMC4578991 Campbell-Thompson M, Fu A, Kaddis JS, Wasserfall C, Schatz DA, Pugliese A, et al. Insulitis and β-Cell Mass in the Natural History of Type 1 Diabetes. Diabetes. 2016;65(3):719-31. https://doi.org/10.2337/db15-0779PMid:26581594 PMCid:PMC4764143 Urbanová J, RypáÄková B, Procházková Z, KuÄera P, Cerná M, AndÄ›l M, et al. Positivity for islet cell autoantibodies in patients with monogenic diabetes is associated with later diabetes onset and higher HbA1c level. Diabet Med. 2014;31(4):466-71. https://doi.org/10.1111/dme.12314PMid:24102923 McDonald TJ, Colclough K, Brown R, Shields B, Shepherd M, Bingley P, et al. Islet autoantibodies can discriminate maturity-onset diabetes of the young (MODY) from Type 1 diabetes. Diabet Med. 2011;28(9):1028-33. https://doi.org/10.1111/j.1464-5491.2011.03287.xPMid:21395678 .Zóka A, Barna G, Somogyi A, Műzes G, Oláh Ã, Al-Aissa Z, et al. Extension of the CD4+Foxp3+CD25(-/low) regulatory T-cell subpopulation in type 1 diabetes mellitus. Autoimmunity. 2015;48(5):289-97. https://doi.org/10.3109/08916934.2014.992518PMid:25523632 Jelsing J, Vrang N, van Witteloostuijn SB, Mark M, Klein T. The DPP4 inhibitor linagliptin delays the onset of diabetes and preserves β-cell mass in non-obese diabetic mice. J Endocrinol. 2012;214(3):381-7. https://doi.org/10.1530/JOE-11-0479PMid:22761275 Julián MT, Alonso N, Colobran R, Sánchez A, Miñarro A, Pujol-Autonell I, et al. CD26/DPPIV inhibition alters the expression of immune response-related genes in the thymi of NOD mice. Mol Cell Endocrinol. 2016;426:101-12. https://doi.org/10.1016/j.mce.2016.02.014PMid:26911933 Lima-Martínez MM, Guerra-Alcalá E, Contreras M, Nastasi J, Noble JA, Polychronakos C. One year remission of type 1 diabetes mellitus in a patient treated with sitagliptin. Endocrinol Diabetes Metab Case Rep. 2014;2014:140072. https://doi.org/10.1530/EDM-14-0072PMid:25332771 PMCid:PMC4190822 Pinheiro MM, Pinheiro FM, Torres MA. Four-year clinical remission of type 1 diabetes mellitus in two patients treated with sitagliptin and vitamin D3. Endocrinol Diabetes Metab Case Rep. 2016;2016. https://doi.org/10.1530/EDM-16-0099PMid:28035286 PMCid:PMC5184778

Published

2020-03-05

Issue

Section

Case Report/Series